4 Aptamer-Based Drug Delivery Systems
107
15. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W (2008) Cellspecific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res
7(5):2133–2139
16. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W (2007) Aptamer directly
evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in
Burkitt’s lymphoma cells. Mol Cell Proteomics 6(12):2230–2238
17. Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics.
Annu Rev Med 56:555–583
18. Moshfeghi AA, Puliafito CA (2005) Pegaptanib sodium for the treatment of neovascular
age-related macular degeneration. Expert Opin Investig Drugs 14(5):671–682
19. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Mones J,
Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC (2017) Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration. Ophthalmology
124(2):224–234
20. Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van
Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM,
Ijpelaar DHT, Rabelink TJ (2017) Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function
in diabetic nephropathy. Amer J Pathol 187(11):2430–2440
21. Povsic TJ, Vavalle JP, Alexander JH, Aberle LH, Zelenkofske SL, Becker RC, Buller CE,
Cohen MG, Cornel JH, Kasprzak JD, Montalescot G, Fail PS, Sarembock IJ, Mehran R,
Investigators R (2014) Use of the REG1 anticoagulation system in patients with acute coronary
syndromes undergoing percutaneous coronary intervention: results from the phase II RADARPCI study. Eurointervention 10(4):431–438
22. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164
23. Huang BT, Lai WY, Chang YC, Wang JW, Yeh SD, Lin EPY, Yang PC (2017) A CTLA-4
antagonizing DNA aptamer with antitumor effect. Mol Ther Nucl Acids 8:520–528
24. Ueki R, Sando S (2014) A DNA aptamer to c-Met inhibits cancer cell migration. Chem Comm
(Cambridge England) 50(86):13131–13134
25. Xiang Q, Tan G, Jiang X, Wu K, Tan W, Tan Y (2017) Suppression of FOXM1 Transcriptional
activities via a single-stranded DNA aptamer generated by SELEX. Sci Rep 7:45377
26. Kowalska E, Bartnicki F, Fujisawa R, Bonarek P, Hermanowicz P, Tsurimoto T, Muszynska K,
Strzalka W (2018) Inhibition of DNA replication by an anti-PCNA aptamer/PCNA complex.
Nucl Acids Res 46(1):25–41
27. Urak KT, Blanco GN, Shubham S, Lin LH, Dassie JP, Thiel WH, Chen YN, Sonkar VK,
Lei BL, Murthy S, Gutierrez WR, Wilson ME, Stiber JA, Klesney-Tait J, Dayal S, Miller
FJ, Giangrande PH (2019) RNA inhibitors of nuclear proteins responsible for multiple organ
dysfunction syndrome. Nat Communicat 10:14
28. Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez
FJ, Liu XY, Wilson ME, Allen LA, Vaena DA, Meyerholz DK, Giangrande PH (2014) Targeted
inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane
antigen. Mol Ther 22(11):1910–1922
29. Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A
(2019) PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol
234(10):16824–16837
30. Lai WY, Huang BT, Wang JW, Lin PY, Yang PC (2016) A novel PD-L1-targeting antagonistic
DNA aptamer with antitumor effects. Mol Ther Nucl Acids 5:9
31. Lai WY, Wang JW, Huang BT, Lin EPY, Yang PC (2019) A novel TNF-alpha-targeting aptamer
for TNF-alpha-mediated acute lung injury and acute liver failure. Theranostics 9(6):1741–
1751
32. Zhu G, Niu G, Chen X (2015) Aptamer-drug conjugates. Bioconjug Chem 26(11):2186–2197
107
15. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W (2008) Cellspecific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res
7(5):2133–2139
16. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W (2007) Aptamer directly
evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in
Burkitt’s lymphoma cells. Mol Cell Proteomics 6(12):2230–2238
17. Nimjee SM, Rusconi CP, Sullenger BA (2005) Aptamers: an emerging class of therapeutics.
Annu Rev Med 56:555–583
18. Moshfeghi AA, Puliafito CA (2005) Pegaptanib sodium for the treatment of neovascular
age-related macular degeneration. Expert Opin Investig Drugs 14(5):671–682
19. Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Mones J,
Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC (2017) Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration. Ophthalmology
124(2):224–234
20. Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van
Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM,
Ijpelaar DHT, Rabelink TJ (2017) Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function
in diabetic nephropathy. Amer J Pathol 187(11):2430–2440
21. Povsic TJ, Vavalle JP, Alexander JH, Aberle LH, Zelenkofske SL, Becker RC, Buller CE,
Cohen MG, Cornel JH, Kasprzak JD, Montalescot G, Fail PS, Sarembock IJ, Mehran R,
Investigators R (2014) Use of the REG1 anticoagulation system in patients with acute coronary
syndromes undergoing percutaneous coronary intervention: results from the phase II RADARPCI study. Eurointervention 10(4):431–438
22. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO (2009) Discovery and development of
the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86(3):151–
164
23. Huang BT, Lai WY, Chang YC, Wang JW, Yeh SD, Lin EPY, Yang PC (2017) A CTLA-4
antagonizing DNA aptamer with antitumor effect. Mol Ther Nucl Acids 8:520–528
24. Ueki R, Sando S (2014) A DNA aptamer to c-Met inhibits cancer cell migration. Chem Comm
(Cambridge England) 50(86):13131–13134
25. Xiang Q, Tan G, Jiang X, Wu K, Tan W, Tan Y (2017) Suppression of FOXM1 Transcriptional
activities via a single-stranded DNA aptamer generated by SELEX. Sci Rep 7:45377
26. Kowalska E, Bartnicki F, Fujisawa R, Bonarek P, Hermanowicz P, Tsurimoto T, Muszynska K,
Strzalka W (2018) Inhibition of DNA replication by an anti-PCNA aptamer/PCNA complex.
Nucl Acids Res 46(1):25–41
27. Urak KT, Blanco GN, Shubham S, Lin LH, Dassie JP, Thiel WH, Chen YN, Sonkar VK,
Lei BL, Murthy S, Gutierrez WR, Wilson ME, Stiber JA, Klesney-Tait J, Dayal S, Miller
FJ, Giangrande PH (2019) RNA inhibitors of nuclear proteins responsible for multiple organ
dysfunction syndrome. Nat Communicat 10:14
28. Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, Chen Y, Hernandez
FJ, Liu XY, Wilson ME, Allen LA, Vaena DA, Meyerholz DK, Giangrande PH (2014) Targeted
inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane
antigen. Mol Ther 22(11):1910–1922
29. Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A
(2019) PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol
234(10):16824–16837
30. Lai WY, Huang BT, Wang JW, Lin PY, Yang PC (2016) A novel PD-L1-targeting antagonistic
DNA aptamer with antitumor effects. Mol Ther Nucl Acids 5:9
31. Lai WY, Wang JW, Huang BT, Lin EPY, Yang PC (2019) A novel TNF-alpha-targeting aptamer
for TNF-alpha-mediated acute lung injury and acute liver failure. Theranostics 9(6):1741–
1751
32. Zhu G, Niu G, Chen X (2015) Aptamer-drug conjugates. Bioconjug Chem 26(11):2186–2197